Regeneron Provides Free Drug Treatment for Medicaid Patients
Regeneron will provide free gene therapy Otarmeni for genetic hearing loss and lower Medicaid prices, the final drug deal in Trump's most-favored-nation pricing initiative.
Objective Facts
President Trump announced a deal with Regeneron on Thursday to lower the cost of its pharmaceutical products as part of the White House's most-favored-nation drug pricing initiative. Under the agreement, Regeneron will provide Otarmeni (lunsotogene parvec-cwha), its recently approved gene therapy for genetic hearing loss, for free in the U.S., and will lower Medicaid prices based on prices in other developed countries. The deal involves selling Praluent for $225 on the White House's discounted drug website TrumpRx, according to the agreement confirmed by White House press secretary Karoline Leavitt. Regeneron is the final one of those companies to strike a deal with his administration. Experts have noted the discounts aren't likely to significantly impact companies' bottom lines, as Medicaid drugs are already highly discounted.
Left-Leaning Perspective
Democrats pressed Health Secretary Robert F. Kennedy Jr. to release details of the agreements, arguing they fall well short of the administration's grand promises and claiming the details are difficult to assess because the agreements remain private. Health policy experts and Democrats panned the Trump administration's drug price deals, with some analysis finding that the prices available through TrumpRx are higher than prices through other discount programs or generic alternatives, and Sen. Ron Wyden released a report questioning the terms of the administration's deals and calling the initiative a "sham." The FDA's Commissioner's National Priority Voucher program, under which Otarmeni was approved, was not authorized by Congress and has been under scrutiny from Democrats for months, with lawmakers noting that FDA vouchers have repeatedly gone to companies that agree to pricing concessions sought by the White House. Left-leaning coverage emphasizes the confidentiality of deal terms and questions whether the pharmaceutical concessions represent genuine savings rather than leveraging process, pointing out that most Americans use private insurance or Medicare—not Medicaid—and therefore would not benefit from the Medicaid price reductions.
Right-Leaning Perspective
Trump announced the 17th deal with a major pharmaceutical company at an Oval Office event, flanked by Cabinet officials and Regeneron executives, stating: "Today, I'm thrilled to announce that one of the most respected pharmaceutical companies anywhere in the world, frankly, I know it very well, is Regeneron, and it's agreed to offer their prescription medications at heavily discounted most-favored-nation prices." The administration highlighted Regeneron's commitment to investing $27 billion by 2029 in U.S. research, development and manufacturing, with the administration noting that total pharmaceutical investments announced under Trump now total $448 billion in roughly 15 months. The White House fact sheet emphasized that the agreement will provide every State Medicaid program access to most-favored-nation drug prices on new Regeneron products, ensuring that foreign nations can no longer use price controls to freeride on American innovation. Right-leaning framing emphasizes the historic scope of the pricing initiative—17 companies covering 80% of the branded drug market—and Trump's direct involvement in personally securing concessions.
Deep Dive
The Regeneron deal represents the final piece of Trump's most-favored-nation pricing initiative, which began with a May 2025 executive order and accelerated through 2025-2026 negotiations. The announcement's timing—on the same day as Otarmeni's FDA approval—created powerful visual imagery linking drug pricing reform to medical innovation. However, the policy's actual impact remains contested. Policy experts and critics note the price concessions are unlikely to significantly affect pharmaceutical companies' bottom lines since Medicaid drug prices are already heavily discounted, and the deals primarily affect Medicaid and direct-to-consumer purchases through TrumpRx, leaving private insurance and Medicare—which cover most Americans—largely unaffected. Some health policy experts have found that prices available through TrumpRx are higher than prices through other discount programs or generic alternatives. The confidential nature of deal terms prevents independent verification. The Otarmeni approval under the FDA's Commissioner's National Priority Voucher program, which was not authorized by Congress, has raised additional scrutiny from Democrats concerned about the program's legitimacy. Regeneron's decision to offer Otarmeni free (rather than charging up to $4 million per patient as some internal parties advocated) demonstrates corporate discretion more than policy mandate. What remains to be seen is whether the 17 deals covering 86% of the branded drug market will influence pharmaceutical pricing patterns broadly, and whether smaller biotech companies will sign similar agreements to avoid threatened tariffs.